TGen review links gene with the most common liver cancer
(The Translational Genomics Research Institute) In an article published in the scientific journal Cancers, researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, provide the first summary of the experimental evidence supporting the AKR1B10 enzyme as a promising therapeutic target for Hepatocellular carcinoma (HCC), based on a review of more than 50 studies published since this gene was first identified and characterized in 1998.
ConclusionsStress conditions induced by locoregional therapies stimulated hCSC enrichment and proliferation, which could be suppressed by niclosamide and inhibitors of pathways important for hCSC renewal. Future studies will determine whether combining locoregional therapies with adjuvant hCSC inhibitors reduces HCC recurrence.
CONCLUSIONS: At current costs, cabozantinib is not cost-effective for second-line therapy of HCC in the United States. PMID: 31200357 [PubMed - in process]
Authors: Gyawali B PMID: 31200350 [PubMed - in process]
ConclusionsOur clinical analyses suggest that in ROC patients with liver disease the assessment of germline and somatic BRCA mutational status can help to select patients elegible for SCS.
Although the prognosis of patients with occult hepatitis B virus (HBV) infection (OBI) is usually benign, a small portion may undergo cirrhosis and subsequently hepatocellular carcinoma (HCC). We studied the m...
Conclusion: Our data indicate that the risk of microvascular invasion is highest in tumors localized to segment 8. The size and number of HCC tumors were not associated with an increased risk of microvascular invasion. PMID: 31186641 [PubMed]
Besides their long-known critical role in embryonic growth and in cancer development and progression, EphB (Erythropoietin-producing hepatocellular carcinoma type B) receptor tyrosine kinases and their ephrin-B ligands are involved in the modulation of immune responses and in remodelling and maintaining the integrity of the intestinal epithelial layer. These processes are critically involved in the pathogenesis of inflammatory-based disorders of the gut, like inflammatory bowel diseases (IBDs). Accordingly, our aim was to investigate the role of the EphB/ephrin-B system in intestinal inflammation by assessing the local and...
Hepatocellular carcinoma (HCC) is one of the leading causes of global cancer-related deaths. The majority of patients present with advanced disease and current medical therapy only prolongs survival by a few months.1 HCC occurs on the background of chronic liver disease in more than 90% of cases and is a paradigm for inflammation-induced cancer where the tumour microenvironment (TME) is characterised by ongoing metabolic stress and an immunosuppressive environment.2 This has led to significant interest in assessing whether immunotherapy could be an effective approach to combat this cancer.
In conclusion, our study demonstrated that intratumoral infiltration by pDCs is a novel indicator for poor prognosis in patients with HCC, possibly through the induction of an immune tolerogenic and inflammatory tumor microenvironment comprising regulatory T and IL-17-producing cells. An assessment of the combination of these cells represents a superior predictor of patient outcome.
AbstractPurposeAs a novel immune-nutritional biomarker, the controlling nutritional status (CONUT) score has been reported to predict outcomes in cancer patients. We aimed to elucidate the prognostic value of preoperative CONUT score and construct a CONUT score-based nomogram to predict individual survival of patients with hepatitis B viral (HBV)-associated hepatocellular carcinoma (HCC) after curative hepatectomy.MethodsPreoperative CONUT score was retrospectively calculated in 380 HBV-associated HCC patients undergoing radical resection between 2006 and 2012. Patients were assigned to two groups: CONUT-low (